For Immediate Release
Company name: DAIICHI SANKYO COMPANY, LIMITED
Representative: Takashi Shoda, President and Representative Director
(Code no.: 4568, First Section, Tokyo, Osaka and Nagoya Stock Exchanges)
Please address inquiries to Toshio Takahashi, Corporate Officer in Charge,
Corporate Communications Department
Telephone: +81-3-6225-1126
http://www.daiichisankyo.co.jp/
Restructuring of Group Companies
Tokyo, November 30, 2006-DAIICHI SANKYO CAMPANY, LIMITED (hereafter: DAIICHI SANKYO) has decided to restructure its group companies as follows as a result of its acquisition of Sankyo Company Limited (hereafter; Sankyo) and Daiichi Pharmaceutical Co., Ltd. (hereafter; Daiichi Pharmaceutical).
1. Integration of healthcare businesses
Outline of new company (scheduled for April 1, 2007) |
Company name |
DAIICHI SANKYO HEALTHCARE CO., LTD. |
Business |
Manufacture and trading of pharmaceutical products, quasi drugs, medical equipment, cosmetics, food products, beverages, etc. |
Main place of business |
Head office (Tokyo); Research Center (Tokyo); Branches (7 locations) |
Location of head office |
Chuo-ku, Tokyo |
Representatives |
Chairman Hidetoshi Imaizumi President Moriya Ideguchi Executive Vice-President Masaji Oe |
Capital |
¥100 million |
FY-end |
March 31 |
Outline of restructuring:
DAIICHI SANKYO HEALTHCARE will acquire Zepharma.
Outline of companies involved in restructuring (as of Sept. 30, 2006) |
Company names |
DAIICHI SANKYO HEALTHCARE CO., LTD. |
Zepharma Inc. |
Business |
Manufacturing & marketing of pharmaceuticals, quasi-drugs, medical equipment, cosmetics, food products, beverages |
Development and sale of pharmaceuticals, quasi-drugs, cosmetics, food products |
Location of head office |
Chuo-ku, Tokyo |
Chuo-ku, Tokyo |
Representatives |
Moriya Ideguchi, President |
Masaji Oe, President |
Capital |
¥100 million |
¥300 million |
Major shareholders & holding ratio |
Sankyo: 67% Daiichi Pharmaceutical: 33% |
DAIICHI SANKYO CO., LTD: 100% |
2. Restructuring of subsidiaries
(1) Production subsidiary
Outline of new company (scheduled for April 1, 2007) |
Company name |
DAIICHI SANKYO PROPHARMA CO., LTD. |
Business |
Manufacture, commissioned manufacture trading, import & export of pharmaceutical products |
Main place of business |
Head office (Tokyo); factories (7 locations) |
Location of head office |
Chuo-ku, Tokyo |
Representatives |
President Masahiro Okabe Executive Vice-President Tatsuro Miyagawa |
Capital |
¥100 million |
FY-end |
March 31 |
Outline of restructuring:
DAIICHI SANKYO PROPHARMA CO., LTD., established in October 2006, will acquire Daiichi Pharmatech Co., Ltd., a subsidiary of Daiichi Pharmaceutical, and will acquire and divide the production division of Sankyo.
(2) R&D support subsidiaries Outline of new company (April 1, 2007) |
Company name |
DAIICHI SANKYO RD ASSOCIE CO., LTD. |
Business |
Commissioned manufacture of test-use specimens and intermediates for use in R&D; consignment of screening tests; commissioned pharmacology tests; commissioned clinical test-related operations |
Main place of business |
Head office (Tokyo) |
Location of head office |
Shinagawa-ku, Tokyo |
Representatives |
President Tomio Kimura Executive Vice-President Toshiro Minotani |
Capital |
¥50 million |
FY-end |
March 31 |
Outline of restructuring
DAIICHI SANKYO RD ASSOCIE CO., LTD., established in October 2006, will acquire the Institute of Science and Technology, Inc. and Chemtec Labo., Inc. of the Sankyo Group and Kanto Daiichi Service Co., Ltd. of the Daiichi Pharmaceutical Group. Furthermore, a number of the R&D operations of the DAIICHI SANKYO Group will be transferred to Daiichi Sankyo RD Associe Co., Ltd.
(3) Management-support subsidiaries Outline of the new company (Scheduled for April 1, 2007) |
Company name |
DAIICHI SANKYO BUSINESS ASSOCIE CO., LTD. |
Business |
Consignment of personnel and accounting operations; leasing, management, buying & selling of real estate and real estate agency services; insurance agency services |
Main place of business |
Head office (Tokyo) |
Representative |
President Yoichi Hara Executive Vice-President Osamu Imada |
Capital |
¥50 million |
FY-end |
March 31 |
Outline of the restructuring
DAIICHI SANKYO BUSINESS ASSOCIE CO., LTD., established in October 2006, will acquire Sankyo Insurance Agency Co., Ltd. and Godo Real Estate Co., Ltd. of the Sankyo Group and Daiichi Estate Co. Ltd. of the Daiichi Pharmaceutical Group. Furthermore, domestic personnel and accounting operations of the DAIICHI SANKYO Group will be transferred in part to DAIICHI SANKYO BUSINESS ASSOCIE CO., LTD.
Other changes |
(1) Logistics subsidiary |
|
On April 1, 2007, we will change the name of Daiichi Butsuryu Co., Ltd. to DAIICHI SANKYO LOGISTICS CO., LTD. and will consolidate our domestic pharmaceutical distribution operations to this company. |
(2) Special subsidiary |
|
We will establish DAIICHI SANKYO HAPPINESS CO., LTD. in March 2, 2007, which will begin operations as a special subsidiary pursuant to the Law for Employment of Disabled Persons on April 2. |
(3) Name of Daiichi Asubio Pharma Co., Ltd to change |
|
As of April 1, 2007, the name of Daichi Asubio Pharma Co., Ltd. will change to ASUBIO PHARMA CO, LTD., while the name of its U.S. subsidiary Daiichi Asubio Pharmaceuticals, Inc. will change to ASUBIO PHARMACEUTICALS, INC. |
End